BATON ROUGE, La., June 15, 2017 / Weed Wire/ — The LSU AgCenter has notified the Board of Supervisors of their intent to contract with GB Sciences, Inc., to produce a medical marijuana product for qualifying patients. GB Sciences will work under the LSU AgCenter license in compliance with state law and rules established by regulatory agencies.
In 2015, the Louisiana legislature enacted a law allowing for the cultivation, production and use of medical marijuana. This law provides that the LSU AgCenter and Southern University Agricultural Center may be licensed for the production of medical marijuana. The medical marijuana programs will be regulated by the Louisiana Department of Agriculture and Forestry, the Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners.
No taxpayer dollars will be spent on the project.
The AgCenter collaborated with multiple university departments, including the President’s Office, Finance and Administration, and Procurement, in addition to working with external consultants to review similar proposals from other states with medical marijuana programs. Each qualifying offer was reviewed by a selection team composed of five members with expertise in administration, finance, medicine, botanical research and analytical chemistry, with oversight from LSU Procurement.
GB Sciences, Inc., scored the highest overall score and was selected to move forward with contract negotiations pending approval by the LSU Board of Supervisors. GB Sciences, Inc., is a publicly-traded medical cannabis company dedicated to scientific innovations that ensure patient safety, therapeutic efficacy and product consistency. The LSU AgCenter is looking forward to research opportunities and the ability to help qualifying medical patients across the state.
More information is available at www.lsuagcenter.com/agmedical.